Small Molecule CDMO Market: By Product (Small Product API and Small Molecule Drug Product [Oral solid dose, Semi-Solid Dose, Liquid Dose, and Others]), By Phase (Preclinical, Clinical, and Commercial), By Customer Type (Pharmaceuticals and Biotechnology), By Therapeutic Area (Cardiovascular Diseases, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Diseases, and Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Small Molecule CDMO Market size was valued at USD 40.6 billion in 2023 and projected to reach USD 74.5 billion by 2030, growing at a 6.4% CAGR from 2024 to 2030. The market of CDMO small molecule has involved only the development of production of molecule drugs and is predicted to increase significantly. Small molecule CDMO companies observed an overall increase in market revenue by 30% in the year 2021, large molecule market has grown comparatively less. The increasing spending on R&D activities and growing demand for small molecules in the market, rising incidence of cardiovascular diseases, respiratory disorders, and other age-related problems are the major factor that drives the market growth. COVID-19 has impacted market growth, during the pandemic a greater number of CDMO initiatives to meet pharmaceutical targets.

The growing healthcare spending escalates the demand for small molecule CDMO, Pharmaceutical companies are focused on core competencies to allow outsourcing activities for manufacturing and development, and CDMO provides wide opportunities for manufacturing facilities. The CDMO market covers 60% of revenue share in manufacturing activities, and the availability of an abundance of small molecule manufacturers hinders the quality issues associated with products which hamper the market growth. The small molecule CDMOs impacted on both drug production and biopharmaceutical products, the companies are consolidating their supplier base and prefer to work with CDMOs and offer various services across drug substances and manufacturing which is the ongoing trend in the market. Geographically, North America held a significant market share in 2022 showing steady growth in the market. Asia Pacific held a major market share in the historic years, and it is predicted to dominate the market in the forecast years.

Small Molecule CDMO Market Key Developments:
  • In April 2022, Novasep, a Lyon, France-based CDMO of APIs and antibody-drug conjugates, and PharmaZell, a Raubling, Germany-based CDMO of small-molecule APIs get merged this strategic merger creates a technology-driven, leading CDMO and API manufacturer

Small Molecule CDMO Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.4%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Small Molecule CDMO Market Dynamics

The increasing prevalence of various age-related diseases across the world is the major market driver in the small-molecule CDMO Market during the forecast period. Cardiovascular drugs, oncology and other diseases are growing across the world a high demand for pharmaceutical products owing to increased CDMO in the market, to accomplish the requirement in the market the pharmaceuticals are consolidating with outsourcing to achieve the need in the market. Hence, this will drive the global market growth at a significant rate.

Key Features of the Reports

  • The small molecule cdmo market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Small Molecule CDMO Market Segmentation

By Product Type
  • Small Product API
  • Small Molecule Drug Product
By Phase
  • Preclinical
  • Clinical
  • Commercial
By Customer Type
  • Pharmaceuticals
  • Biotechnology
By Therapeutic Area
  • Cardiovascular Diseases
  • Oncology
  • Respiratory Disorders
  • Neurology
  • Metabolic Disorders
  • Infectious Diseases
  • Others

Frequently Asked Questions

The small molecule cdmo market size was valued at USD 40.6 billion in 2023 and is projected to reach USD 74.5 billion by 2030.

The small-molecule cdmo market is poised to grow at a significant CAGR of 6.4% from 2024 to 2030.

The leading players in the Small Molecule CDMO Market are Piramal Pharma Solutions, CordenPharma International, Wuxi AppTec, Cambrex Corporation, Recipharm AB, Pantheon (Thermo Fisher Scientific), Lonza, Catalent Inc., Siegfried Holding AG, Boehringer Ingelheim, and Labcorp Drug Development.

  • Piramal Pharma Solutions
  • CordenPharma International
  • Wuxi AppTec
  • Cambrex Corporation
  • Recipharm AB
  • Pantheon (Thermo Fisher Scientific)
  • Lonza
  • Catalent Inc.
  • Siegfried Holding AG
  • Boehringer Ingelheim
  • Labcorp Drug Development

Adjacent Markets